About eli lilly & co. - LLY
LLY At a Glance
Phone | 1-317-276-2000 | Revenue | 45.04B | |
Industry | Pharmaceuticals: Major | Net Income | 10.59B | |
Sector | Health Technology | 2024 Sales Growth | 31.997% | |
Fiscal Year-end | 12 / 2025 | Employees | 47,000 | |
View SEC Filings |
LLY Valuation
P/E Current | 71.707 |
P/E Ratio (with extraordinary items) | N/A |
P/E Ratio (without extraordinary items) | 65.905 |
Price to Sales Ratio | 15.495 |
Price to Book Ratio | 51.543 |
Price to Cash Flow Ratio | 79.15 |
Enterprise Value to EBITDA | 38.722 |
Enterprise Value to Sales | 16.168 |
Total Debt to Enterprise Value | 0.046 |
LLY Efficiency
Revenue/Employee | 958,355.319 |
Income Per Employee | 225,319.149 |
Receivables Turnover | 3.393 |
Total Asset Turnover | 0.631 |
LLY Liquidity
Current Ratio | 1.154 |
Quick Ratio | 0.886 |
Cash Ratio | 0.121 |
LLY Profitability
Gross Margin | 81.31 |
Operating Margin | 37.831 |
Pretax Margin | 28.152 |
Net Margin | 23.511 |
Return on Assets | 14.84 |
Return on Equity | 84.842 |
Return on Total Capital | 22.138 |
Return on Invested Capital | 29.494 |
LLY Capital Structure
Total Debt to Total Equity | 237.063 |
Total Debt to Total Capital | 70.332 |
Total Debt to Total Assets | 42.742 |
Long-Term Debt to Equity | 201.007 |
Long-Term Debt to Total Capital | 59.635 |
Eli Lilly & Co. in the News
These companies have announced their intention to increase US manufacturing
Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor Group and others.
Weight-loss drugs entering 'new era' with breakthrough daily pill
Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets in 2026. It reportedly works as well as Ozempic.
Pfizer will end development of daily weight-loss pill after liver injury
Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.
Eli Lilly cuts prices for Zepbound weight-loss drug again
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Running low on Ozempic or another weight loss drug? A new tracker can help
Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.
Nestlé launches food line targeting Ozempic, other weight-loss drug users
Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.
25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.
Meet Disney's newly elected board
Disney CEO Bob Iger will be working closely with his newly elected board, which boasts a handful of current and former Fortune 500 executives and some niche corporate insiders.
Amazon Pharmacy will deliver Eli Lilly's Zepbound, other drugs to customers' doorsteps
Amazon Pharmacy is now a third-party dispensing provider for LillyDirect, the pharmaceutical company's telehealth platform, and gives patients access to more weight-loss drugs.
Experts express concern over pharmaceutical giant Eli Lilly's new website connecting patients to obesity drugs
Eli Lilly, which makes obesity and diabetes drugs like Zepbound and Mounjaro, has launched a new website that connects patients to telehealth services, but the service worries some health experts.